Drug Cos. Made Record Pay-For-Delay Deals In 2011: FTC

Law360, New York (October 25, 2011, 1:41 PM EDT) -- Pharmaceutical companies racked up record numbers of so-called reverse payment patent settlements in 2011 designed to delay the release of a rival generic drug, the Federal Trade Commission said Tuesday, calling it an anti-competitive practice that costs consumers and the U.S. government billions.

Drug companies entered into 28 potential pay-for-delay deals in fiscal year 2011 — from Oct. 1, 2010, to Sept. 30 — nearly matching last year's high of 31 deals, and higher than any other previous year since the FTC began collecting industry data...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.